Extending the half-life of antibodies
With world-renowned capabilities in antibody discovery and protein engineering, a small team at MedImmune was faced with seemingly basic science – extend the half-life of an antibody. For patients, an extended half-life requires fewer doses of medication.
Where’s the future of biotech? Right here in Maryland.
The first ever Maryland Regional Biotech Forum, hosted by MedImmune, drew more than 400 leaders of local life sciences companies, academic institutions, nonprofit organizations, investment funds and government entities. The goal: outline concrete steps toward our commitment to make the Maryland region one of the top three biotech hubs in the United States by 2023.
Power tool for cancer therapy
CRUK-MedImmune Alliance Laboratory (CMAL) - located in Cambridge - is exciting because we’re bringing together researchers from both of our organizations to collaborate with the goal of discovering and developing biologics to treat and diagnose cancer. But, more specifically, where Cancer Research UK will contribute its cancer biology proficiency, MedImmune offers access to its protein engineering expertise and its vast human antibody phage display (PD) libraries.